What is new in chronic lymphocytic leukemia (CLL)? (Episode 2)
1 Views
administrator
07/08/23
Venetoclax is a BCL2 inhibitors. Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor known to have cardiovascular adverse events, including hypertension and arrhythmias.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL was investigated by the CAPTIVATE study aiming to decrease these BTK inhibitors related toxicity.
Dr. Ahmed Magdy summarized the outstanding results of CAPTIVATE FD trial. watch it now!
-
Category
Show more
Facebook Comments
![Erections After Prostate Cancer Treatment with Robert Valenzuela, MD [Episode 45]](https://i.ytimg.com/vi/eerLyyQeibs/maxresdefault.jpg)
No comments found